Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status:
Recruiting
Trial end date:
2022-09-11
Target enrollment:
Participant gender:
Summary
This phase I/II trial identifies the best dose of seclidemstat when given together with
azacitidine in treating patients with myelodysplastic syndrome or chronic myelomonocytic
leukemia. Seclidemstat may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Azacitidine may help block the formation of growths that may become
cancer. Giving seclidemstat and azacytidine may kill more cancer cells.